During the past decade, Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 3 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie" #1 sponsor was "Hoffmann-La Roche" with 5 trials, followed by "BioNTech SE" with 1 trials sponsored, "Genentech, Inc." with 1 trials sponsored, "Genmab" with 1 trials sponsored and "IO Biotech" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie" #1 collaborator was "BioNTech SE" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Syneos Health" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie" are "Basal Cell Carcinoma" (2 trials), "Malignant Melanoma" (2 trials), "Melanoma" (2 trials), "Advanced BRAFV600 Wild-type Melanoma" (1 trials) and "Advanced Melanoma" (1 trials). Many other conditions were trialed in "Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie" in a lesser frequency.

Most popular intervention types in "Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie" are "Drug" (8 trials), "Biological" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (4 trials), "Nivolumab" (2 trials), "5-FU" (1 trials), "Atezolizumab" (1 trials) and "Carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".